VLFA08222p Pharmacology II - lecture

Faculty of Medicine
spring 2026
Extent and Intensity
2/0/0. 3 credit(s). Type of Completion: zk (examination).
In-person direct teaching
Teacher(s)
doc. MUDr. Regina Demlová, Ph.D. (lecturer)
doc. PharmDr. Jan Juřica, Ph.D. (lecturer)
Mgr. Petra Amchová, Ph.D. (lecturer)
doc. RNDr. Ladislava Bartošová, Ph.D. (lecturer)
MVDr. Eva Dražanová, Ph.D. (lecturer)
PharmDr. Valentína Focková, PhD. (lecturer)
Mgr. Jana Kubátová, Ph.D. (lecturer)
doc. Mgr. MVDr. Leoš Landa, Ph.D. (lecturer)
MUDr. Alena Máchalová, Ph.D. (lecturer)
MUDr. Jana Nováková, Ph.D. (lecturer)
MUDr. Jana Pistovčáková, Ph.D. (lecturer)
doc. PharmDr. Jana Rudá, Ph.D. (lecturer)
Mgr. Barbora Říhová, Ph.D. (lecturer)
PharmDr. Lenka Součková, Ph.D. (lecturer)
Mgr. Nina Beňadik Zemanová, Ph.D. (lecturer)
doc. PharmDr. Ondřej Zendulka, Ph.D. (lecturer)
Carlos Daniel Ferreira Fonseca, MSc. (alternate examiner)
Renata Bláblová (assistant)
Mgr. Marta Vyoralová (assistant)
PharmDr. Petr John (alternate examiner)
PharmDr. Katarína Kostolanská, Ph.D. (alternate examiner)
Guaranteed by
doc. MUDr. Regina Demlová, Ph.D.
Department of Pharmacology – Theoretical Departments – Faculty of Medicine
Contact Person: Mgr. Barbora Říhová, Ph.D.
Supplier department: Department of Pharmacology – Theoretical Departments – Faculty of Medicine
Timetable
Mon 16. 2. 16:00–17:40 Virtuální místnost, Mon 23. 2. 16:00–17:40 Virtuální místnost, Mon 2. 3. 16:00–17:40 Virtuální místnost, Mon 9. 3. 16:00–17:40 Virtuální místnost, Mon 16. 3. 16:00–17:40 Virtuální místnost, Mon 23. 3. 16:00–17:40 Virtuální místnost, Mon 30. 3. 16:00–17:40 Virtuální místnost, Mon 6. 4. 16:00–17:40 Virtuální místnost, Mon 13. 4. 16:00–17:40 Virtuální místnost, Mon 20. 4. 16:00–17:40 Virtuální místnost, Mon 27. 4. 16:00–17:40 Virtuální místnost, Mon 4. 5. 16:00–17:40 Virtuální místnost, Mon 11. 5. 16:00–17:40 Virtuální místnost, Mon 18. 5. 16:00–17:40 Virtuální místnost, Mon 25. 5. 16:00–17:40 Virtuální místnost
Prerequisites (in Czech)
VLFA07212p Pharmacology I
Course Enrolment Limitations
The course is also offered to the students of the fields other than those the course is directly associated with.
fields of study / plans the course is directly associated with
Abstract
The aim of the course is to introduce students to the basic pharmacological profiles of selected groups of drugs (indications, mechanism of action, pharmacokinetic properties, methods of application, adverse effects, drug interactions, and contraindications), with the principles of selecting the appropriate drug for a specific patient, and to apply theoretical knowledge at the level of selecting the appropriate drug to ensure safe and effective pharmacotherapy.
Learning outcomes
After completing the course, students will have an overview of the drug groups used in clinical practice, be familiar with the basic pharmacological profiles of individual drugs, and be able to select and prescribe a medicinal product for a patient based on a known diagnosis, using the available information and a drug database. The choice of drug is based on consideration of all factors affecting its safety and effectiveness.
Key topics

  • VLFA08222p - Pharmacology II lecture

    Spring semester

  • 1. INTRODUCTION TO PSYCHOPHARMACOLOGY, ANTIPSYCHOTICS, ANTIPARKINSONICS
  • Lecture content: Overview of neurotransmitters and their functions. History and classification of psychotropic substances. Antipsychotics, antiparkinsonics – basic pharmacological review.
  • 2. ANTIDEPRESSANTS
  • Lecture content: Pharmacological review of antidepressants and their clinical use.
  • 3. ANXIOLYTICS, HYPNOSEDATIVES, ANTICONVULSANTS
  • Lecture content: Anxiolytics, hypnosedatives, anticonvulsants - basic pharmacological review. The possibilities of modulation of GABAergic neurotransmission.
  • 4. GENERAL AND LOCAL ANAESTHETIC AGENTS
  • Lecture content: Classification and pharmacological characteristics of general and local anaesthetic drugs.
  • 5. VASODILATORS
  • Lecture content: Hypolipidemic drugs, antiobesity drugs, nitrates, Ca channel blockers - DHP. Risk factors of cardiovascular disorders. Pharmacotherapy of dyslipidaemia and ischaemic heart disease.
  • 6. DRUGS INFLUENCING RAAS, DIURETICS
  • Lecture content: ACE inhibitors, AT-II receptor antagonists, renin antagonists, diuretics, mineralocorticoid receptor antagonists. Antihypertensives.
  • 7. DRUGS INFLUENCING MYOCYTES
  • Lecture content: Beta-blockers and bradines, positive inotropics, Ca channel blockers - nonDHP, antiarrhythmic drugs. Drugs in heart failure.
  • 8. DRUGS INFLUENCING HAEMOSTASIS
  • Lecture content: Pharmacological review of anticoagulants, antiplatelets, fibrinolytics, and haemostatics
  • 9. THERAPY OF INTOXICATIONS
  • Lecture content: Review of most common intoxications and their symptomatology. General principles of poisoning management. Specific antidotes in poisoning therapy.
  • 10. ANTI-INFECTIVES I - ANTIBIOTICS
  • Lecture content: Introduction/principles of ATB therapy, mechanisms of bacterial resistance, pharmacological profiles of ATBs.
  • 11. ANTI-INFECTIVES II – ANTIMYCOTICS AND ANTIVIRALS
  • Lecture content: Systemic and local antimycotics; antiherpetics; pharmacotherapy of influenza; antiretrovirals; therapy of RSV and viral hepatitis – pharmacological review.
  • 12. PHARMACOLOGY OF GIT – ULCER DISEASE, ANTIEMETICS, ANTIDIARRHEALS AND LAXATIVES
  • Lecture content: Pharmacological review of drugs acting on GIT.
  • 13. CYTOSTATICS AND TARGETED DRUGS IN ONCOLOGY
  • Lecture content: Introduction. Classification of cytostatics according to their mechanisms of action. Mechanisms of resistance to anticancer drugs. Role of single nucleotide polymorphisms (SNPs) and TDM in oncology. Basic pharmacological properties of selected cytostatics. Principles of targeted therapy in oncology. Monoclonal antibodies. Protein kinase inhibitors. Targeted immunotherapy.
  • 14. DRUG-DRUG INTERACTIONS
  • Lecture content: Classification of drug-drug interaction, evaluation of clinical relevance and seriousness oc drug interactions, management of drug interactions, possibilities of drug interactions monitoring, case-reports.
  • 15. PHYTOPHARMACOLOGY AND PHARMACOGNOSY
  • Lecture content: Natural sources of medicines, selected groups of herbal active components, herbal preparations. The most common herbal poisons.
Study resources and literature
    required literature
  • RITTER, James; R. J. FLOWER; Graeme HENDERSON; Yoon Kong LOKE; David J. MACEWAN and H. P. RANG. Rang and Dale's pharmacology. Ninth edition. Edinburgh: Elsevier, 2020, xvi, 789. ISBN 9780702074486. info
  • RITTER, James, R. J. FLOWER, Graeme HENDERSON, Yoon Kong LOKE, David J. MacEWAN, Emma ROBINSON, James FULLERTON. Rang and Dale's pharmacology. Tenth edition. Elsevier, 2023. 850 p. ISBN 9780323873956.
  • Studijní materiály z IS pod kódem předmětu https://is.muni.cz/auth/el/med/jaro2026/VLFA08222p/um/
  • Landa Leoš, Jan Juřica, Kristýna Nosková, Ondřej Zendulka: Vybrané kapitoly z obecné farmakologie pro studenty všeobecného a zubního lékařství na LF MU. Multimediální podpora výuky klinických a zdravotnických oborů :: Portál Lékařské fakulty Masarykovy
    recommended literature
  • RANG, H. P.; James RITTER; R. J. FLOWER and Graeme HENDERSON. Rang & Dale's pharmacology. Eighth edition. [Edinburgh]: Churchill Livingstone, 2016, xv, 760. ISBN 9780702053627. info
  • http://search.ebscohost.com/login.aspx?direct=true&db=nlebk&AN=1160493&lang=cs&site=ehost-live
  • Farmakologie. Edited by Jan Švihovec - Jan Bultas - Pavel Anzenbacher - Jaroslav Chládek - J. 1. vydání. Praha: Grada Publishing, 2018, xix, 962. ISBN 9788024755588. info
    not specified
  • Osnovy zkouškových otázek
  • http://portal.med.muni.cz/modules.php?name=News&file=article&sid=367
  • Markova farmakoterapie vnitřních nemocí. Edited by Josef Marek - Michal Vrablík. 5., zcela přepracované a d. Praha: Grada, 2019, xxiv, 868. ISBN 9788024750781. info
  • STEVENS, Craig W. Brenner and Stevens' pharmacology. Sixth edition. Philadelphia, PA: Elsevier, 2023, viii, 594. ISBN 9780323758987. info
  • WALLER, Derek; Anthony P. SAMPSON and Andrew W. HITCHINGS. Medical pharmacology and therapeutics. Sixth edition. London: Elsevier, 2022, vii, 742. ISBN 9780702081590. info
  • BROWN, M. J.; Pankaj SHARMA; Fraz A. MIR and P. N. BENNETT. Clinical pharmacology. Twelfth edition. Edinburgh: Elsevier, 2019, 1 online. ISBN 9780702073304. URL info
Approaches, practices, and methods used in teaching
Teaching takes the form of video recordings of lectures published in the IS; students are in regular contact with teachers in follow-up seminars, where individual topics are discussed in detail. Regular consultation hours are scheduled in addition to teaching.
Method of verifying learning outcomes and course completion requirements
The final assessment of the course takes into account the student's results for the two-semester study of pharmacology as follows:

Relative weight of the mark from tests: 30 %
Relative weight of the mark from oral exam: 70 %

To calculate the mark from the tests, the following method will be used:
The summary score from all tests in courses VLFA07212c, VLFA07212p, VLFA08222c, and VLFA08222p is 230 pts. The minimum to pass the course and proceed to the oral exam is 128 pts.
A = 210-230 pts
B = 190-209 pts
C = 160-189 pts
D = 140-159 pts
E = 128-139 pts
F = less than 128 pts

To calculate the mark from the oral exam, the following method will be used:
Students choose three questions from three sets in the oral exam. Moreover, the student answers additional questions from the examiner. Drawn questions from General and Special pharmacology, and the additional questions have a relative weight of 30 %. The question on essential drugs carries a relative weight of 10% in the final mark of the oral exam. When a student is evaluated by F for any of these questions, the overall rating of the oral exam is also F.

In case of success with the ROPOT test (at least 40 pts.), but classification F from the oral part, students enter the oral part next time, and for the final mark, the score from the last ROPOT attempt is used.
Alternate completion
Lectures are provided as video recordings in IS, allowing study while abroad. The exam must be taken in person after returning from the internship.
Language of instruction
Czech
Study support
https://is.muni.cz/auth/el/med/jaro2026/VLFA08222p/um/
Further comments (probably available only in Czech)
The course is taught annually.
Listed among pre-requisites of other courses

Zobrazit další předměty

Teacher's information
General pharmacology: 1. Pharmacology, sub-branches, origin of drugs, drug names 2. Types of pharmacotherapy and rules for rational and safe pharmacotherapy. The question of drug misuse. 3. Preclinical and clinical trials, stages. 4. Basic legislation related to drug use, Sources of information on drugs and medicinal products. 5. Solid and gaseous pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics. 6. Semi-solid and liquid pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics. 7. Routes of drug administration – overview, characteristics. 8. Drug absorption, presystemic elimination, and drug bioavailability. 9. Drug distribution, volume of distribution, and redistribution. General principles of drug movement through the body. 10. Drug elimination, processes of the first and zero order, and drug accumulation. 11. Drug biotransformation – stages, examples. 12. Drug excretion (ways of excretion, possibilities of their influence). 13. Therapeutic monitoring of drugs (TDM). 14. Pharmacokinetics of single, repeated and continual drug administration. 15. Modes of drug action. 16. Synergism and antagonism in drug effect (pharmacokinetics, pharmacodynamics). 17. Dose–response curves, types of doses, drug anamnesis, patient‘s adherence. 18. Adverse drug reactions (types, categories, examples). 19. Pharmacovigilance, drug safety. 20. Influence of repeated administration (tolerance and tachyphylaxis) - examples. Primary resistance of the patient to the treatment. 21. Factors influencing the drug effect – examples. 22. Pharmacotherapy in the elderly, the influence of co-morbidities on drug effect, and polypharmacy. 23. Pharmacotherapy in the paediatric population, in breastfeeding women. Drugs influencing breastfeeding. 24. Pharmacotherapy in pregnancy, drug teratogenicity. 25. Pharmacogenetics, influence of genetic polymorphisms on pharmacokinetics and pharmacodynamics of drugs. 26. Pharmacokinetic drug interactions (desirable and undesirable) - overview, examples. 27. Pharmacodynamic drug interactions (desirable and undesirable) - overview, examples. 28. Principles of biological treatment – classification, technology, examples of clinical use. Special pharmacology: 1. Sympathomimetics - overview of single classes and their indications, examples of drugs 2. Sympatholytics - overview of single classes and their indications, examples of drugs 3. Cholinomimetics 4. Cholinolytics 5. Antispasmodics - GIT + UGT 6. Opioid analgesics 7. NSAIDs, non-opioid analgesics, and antimigraine agents 8. Antiuratics, antirheumatics incl. DMARDs 9. General anaesthetics 10. Local anaesthetics 11. Muscle relaxants 12. Antidiabetics (except insulins) 13. Insulins 14. . Analogues and antagonists of oestrogenes, gestagenes and androgenes – their basic pharmacology; HRT, hormonal contraception 15. Analogues and antagonists of H-P axis hormones used in pharmacology; uterotonics and tocolytics 16. Glucocorticoids 17. Immunostimulants + immunosuppressants (except glucocorticoids) 18. Drugs used in osteoporosis, pharmacology of the thyroid gland 19. Antiasthmatics, drugs used in COPD 20. Antitussives, mucoactive drugs 21. H1 antihistamines 22. Antipsychotics 23. Drugs for neurogenerative diseases (Parkinson’s disease; dementia) 24. Antidepressants - iMAO+SSRI+NDRI 25. Antidepressants - tricyclic, NASSA, MASSA, SARI, SNRI, NARI, SMS 26. Nootropics, cognitive enhancers 27. Psychostimulants. Drugs used in ADHD. Psychomimetics. 28. Anticonvulsants 29. Hypnosedatives, anxiolytics 30. Principles of antibacterial therapy – overview, modes of action, resistance, MIC, MBC 31. Penicillins, carbapenems 32. Cephalosporines, monobactams 33. Tetracyclines + related ATBs, amphenicoles 34. Macrolides and related ATBs, lincosamides 35. Aminoglycosides, glycopeptides, polymyxins 36. Sulphonamides, nitrofurans and nitroimidazoles 37. Quinolones, antituberculotics 38. Antimycotics 39. Dermatologics – overview of classes, drugs and effects 40. Antivirotics 41. Antiemetic drugs, prokinetics, antivertigo drugs 42. Laxatives, antidiarrheals, drugs for infectious diarrhoea 43. Antiulcer agents, hepatoprotectives and drugs influencing the production and excretion of bile 44. Drugs for non-specific inflammatory bowel disease 45. Alkylating cytostatics and other drugs targeting DNA in oncology 46. Antimetabolites + hormonal therapy in oncology 47. Targeted treatment in oncology 48. Biological treatment of autoimmune diseases 49. Hypolipidemics, anti-obesity drugs 50. Nitrates and other vasodilators 51. Drugs targeting RAAS 52. Diuretics and aldosterone antagonists 53. Beta blockers + central antihypertensives 54. Calcium channel blockers, α1-lytics 55. Antiarrhythmics 56. Positive inotropic drugs 57. Antiplatelet agents, antianemics 58. Fibrinolytics, antifibrinolytics, hemostatics 59. Anticoagulants 60. Drugs causing addiction and substances used for the treatment of addiction 61. General principles of drug poisoning, specific antidotes and their mechanisms of action 62. Drugs used in erectile dysfunction and BHP 63. Antiglaucomatics and cycloplegics „Essential drugs“ 5-fluorouracil • acetylcysteine • acetalsalicylic acid • aciclovir • allopurinol • amiodarone • amlodipine • amphotericin B • aprepitant • atorvastatin • atropine • betahistine • buprenorphine • carbamazepine • caspofungin • cefuroxime • cetirizine • ciclosporine • ciprofloxacin • cisplatin • clarithromycin • clopidogrel • co-amoxicillin • codeine • cotrimoxazole • cyclophosphamide • cyproterone • dabigatran • desflurane • diazepam • digoxin • dobutamine • doxazosin • doxorubicin • doxycycline • empagliflozin • enoxaparin • escitalopram • ethinylestradiol • ezetimibe • famotidine • fenpiverine/pitofenone •fentanyl • finasteride • fluconazole • furosemide • gabapentin • gentamicin • haloperidol • hexoprenaline • ibuprofen • imatinib • indapamide • indometacin • interferons • insulin analogues • ipratropium-bromide • isosorbide dinitrate • ketamine • lactulose • levodopa/carbidopa • levonorgestrel • lidocaine • linagliptin • lithium • loperamide • meropenem • metamizole • metformin • methadone • methotrexate • methyldopa • methylphenidate • metoclopramide • metoprolol • mirtazapine • morphine • naloxone • nimesulide • nivolumab • noradrenaline • olanzapine • ondansetron • oxymetazoline • oxytocin • paclitaxel • pantoprazole • paracetamol • perindopril • phenoxymethylpenicillin • pilocarpine • piperacillin/tazobactam • prednisone • propofol • rivaroxaban • rivastigmine • salbutamol • sildenafil • solifenacin • spironolactone • sumatriptan • suxamethonium • tamoxifen • telmisartan • tenofovir • terbinafine • tramadol • trastuzumab • valproic acid • vancomycin • verapamil • warfarin • zolpidem •
The course is also listed under the following terms spring 2019, spring 2020, spring 2021, spring 2022, spring 2023, spring 2024, spring 2025.
  • Enrolment Statistics (recent)
  • Permalink: https://is.muni.cz/course/med/spring2026/VLFA08222p